Cargando…
Vivo-Morpholino-Based Antiviral for SARS-CoV-2: Implications for Novel Therapies in the Treatment of Acute COVID-19 Disease
Therapeutic modalities designed specifically to inhibit COVID-19 infection and replication would limit progressive COVID-19-associated pulmonary disease in infected patients and prevent or limit systemic disease. If effective, antivirals could reduce viral transmission rates by reducing viral burden...
Autores principales: | Hildreth, James E. K., Moulton, Jon D., Alcendor, Donald J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394971/ https://www.ncbi.nlm.nih.gov/pubmed/34440222 http://dx.doi.org/10.3390/biomedicines9081018 |
Ejemplares similares
-
Inhibition and Escape of SARS-CoV Treated with Antisense Morpholino Oligomers
por: Neuman, Benjamin W., et al.
Publicado: (2006) -
Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos
por: Moulton, Jon D., et al.
Publicado: (2009) -
Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds
por: Nan, Yuchen, et al.
Publicado: (2018) -
Advanced morpholino oligomers: A novel approach to antiviral therapy
por: Warren, Travis K., et al.
Publicado: (2012) -
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)